Nuvectis Pharma, Inc. (NASDAQ:NVCT) Short Interest Down 18.1% in July

Nuvectis Pharma, Inc. (NASDAQ:NVCT) saw a significant decrease in short interest in the month of July. As of July 15th, there was short interest totalling 884,200 shares, a decrease of 18.1% from the June 30th total of 1,080,000 shares. Based on an average daily trading volume, of 96,000 shares, the short-interest ratio is presently 9.2 days. Approximately 12.0% of the company’s stock are short sold.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $21.00 target price on shares of Nuvectis Pharma in a report on Wednesday, May 8th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Edmond DE Rothschild Holding S.A. acquired a new position in Nuvectis Pharma in the fourth quarter worth about $160,000. Strs Ohio grew its position in shares of Nuvectis Pharma by 59.0% in the 4th quarter. Strs Ohio now owns 6,200 shares of the company’s stock worth $51,000 after acquiring an additional 2,300 shares in the last quarter. Blue Zone Wealth Advisors LLC acquired a new position in shares of Nuvectis Pharma in the 1st quarter worth approximately $118,000. Vanguard Group Inc. raised its position in shares of Nuvectis Pharma by 1.5% during the 1st quarter. Vanguard Group Inc. now owns 298,800 shares of the company’s stock valued at $2,450,000 after acquiring an additional 4,517 shares in the last quarter. Finally, Baxter Bros Inc. bought a new position in Nuvectis Pharma during the second quarter worth $79,000. Hedge funds and other institutional investors own 96.77% of the company’s stock.

Nuvectis Pharma Stock Performance

Shares of NVCT stock traded down $0.41 on Monday, hitting $6.53. The stock had a trading volume of 99,578 shares, compared to its average volume of 96,931. The stock’s 50 day moving average is $6.54 and its 200-day moving average is $7.39. The firm has a market capitalization of $119.89 million, a price-to-earnings ratio of -4.63 and a beta of 0.46. Nuvectis Pharma has a 52-week low of $5.85 and a 52-week high of $15.50.

Nuvectis Pharma (NASDAQ:NVCT) last issued its quarterly earnings data on Tuesday, May 7th. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.15. Equities analysts expect that Nuvectis Pharma will post -1.29 earnings per share for the current year.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.